As shown in Figure 3D, they observed that the anti-VEGF drugs not only increased the content of CX3CL1 and CXCL5 in tumor vessels but also promoted the recruitment of neutrophils, resulting in the release of a large amount of the cytokine IL-10 to inhibit the adaptive immunity [121]. The gene discussed is VEGFA; the disease is neoplasm.